Peptides for Bone Healing: Evidence Review for Fracture Recovery Research

Key Takeaways

• Compounds covered: BPC-157, GH secretagogues (ipamorelin, CJC-1295, sermorelin), GHK-Cu
• Goal area: Fracture recovery and bone healing support
• Evidence range: Ranges from animal studies (BPC-157 segmental defect model), Mendelian randomization and mechanistic data (GH secretagogues via IGF-1), to in vitro data (GHK-Cu); no completed Phase 3 human RCT for bone healing exists for any profiled compound.
• Regulatory range: Includes compounded peptides (GH secretagogues under Section 503A), substances outside any FDA-permissible compounding category (BPC-157, removed from Category 2 on April 22, 2026), and no FDA-approved compound in this list for bone healing specifically (teriparatide is FDA-approved but is a separate class discussed in context)
• Key biomarkers for bone healing: IGF-1, vitamin D (25-hydroxy), calcium, alkaline phosphatase (ALP), comprehensive metabolic panel
• As of April 22, 2026: FDA removed BPC-157 from the Category 2 list of bulk drug substances under 503A/503B consideration; BPC-157 is outside any FDA-permissible compounding category and is not legally available through US prescribers. On the same date, FDA's Pharmacy Compounding Advisory Committee (PCAC) recommended AGAINST inclusion of CJC-1295 and ipamorelin on the 503A Bulks List; 503A compounding of these peptides is actively contracting. Sermorelin, as a GHRH analog in the same class, is under the same FDA and PCAC review. None are FDA-approved for bone healing.
• Bottom line: BPC-157 has a preclinical animal-study evidence base led by the 1999 Sebecic et al. rabbit defect model; GH secretagogues have population-level IGF-1 evidence linked to bone mineral density but no fracture-healing RCT data; human RCT data for bone healing are absent across all profiled compounds.

Understanding Bone Healing: The Biology

Fracture healing proceeds through four overlapping phases: hematoma formation and inflammatory signaling, soft callus formation (fibrocartilaginous), hard callus mineralization (woven bone), and remodeling (replacement of woven bone with lamellar bone). Each phase involves distinct cell types, growth factor cascades, and vascular requirements. The process typically completes in 6 to 8 weeks for uncomplicated fractures in young adults, but can extend to months or fail in older adults, smokers, patients with metabolic bone disease, or those with large segmental defects.

A 2025 review by Bikle in Frontiers in Endocrinology reviewed fracture healing cellular mechanisms and the role of parathyroid hormone analogs, establishing the biological cascade as the foundation against which investigational peptide mechanisms are typically evaluated. The angiogenic phase is particularly rate-limiting: bone callus formation requires vascular invasion, and any compound that enhances revascularization of the fracture site has been proposed to support the downstream mineralization phases in preclinical models. This is one reason BPC-157, a peptide with preclinical pro-angiogenic activity, has attracted attention in bone healing research.

The GH/IGF-1 axis provides a separate but equally important biological target. Osteoblasts, the cells responsible for new bone matrix synthesis, are direct targets of IGF-1 signaling. A Mendelian randomization study by Yuan and colleagues, published in the Journal of Clinical Endocrinology and Metabolism in 2021, provided Mendelian-randomization evidence for a causal relationship between IGF-1 levels, bone mineral density, and fracture risk in a human population, providing unusually strong epidemiological evidence that the GH/IGF-1 axis is a genuine biological determinant of bone health. Epidemiological work by Dennison and colleagues, published in the Journal of Rheumatology in 2009, confirmed that GH/IGF-1 axis genetic variants associate with bone mass in the Hertfordshire cohort. A 2026 review by Yao and colleagues in Frontiers in Endocrinology reviewed bone microenvironment regulators in osteoporosis and novel intervention strategies for aging, contextualizing the GH/IGF-1 axis within the broader bone aging landscape.

Peptides Studied for Bone Healing: A Quick Comparison

The following peptides have published evidence relevant to bone healing and fracture recovery. They are listed by strength of clinical evidence, from most-studied to least.

• Compound: GH secretagogues (ipamorelin, CJC-1295, sermorelin)
  Mechanism for bone healing: Stimulate pituitary GH release, which drives IGF-1 and osteoblast anabolic signaling; support subchondral bone density and bone mineral density
  Evidence: Mendelian randomization (Yuan et al., 2021) and epidemiological data for IGF-1/bone density link; no RCT specifically for fracture healing
  FDA status: Not FDA-approved for bone healing. Historically compounded under Section 503A; PCAC recommended against CJC-1295 and ipamorelin inclusion on the 503A Bulks List on April 22, 2026; sermorelin is under the same FDA and PCAC review. 503A availability is actively contracting.
  SP availability: Not currently offered through Superpower for bone healing
  Route: Subcutaneous injection
• Compound: BPC-157
  Mechanism for bone healing: Pro-angiogenic activity supports vascular invasion phase of callus formation in preclinical models; osteogenic effects reported in preclinical segmental defect models
  Evidence: Foundational rabbit bone defect study (Sebecic et al., 1999); supporting animal studies; no human RCT
  FDA status: Not FDA-approved; removed from FDA Category 2 list on April 22, 2026; outside any FDA-permissible compounding category
  SP availability: Not currently available through Superpower
  Route: Research use only; no legal human administration pathway under current US regulatory status
• Compound: GHK-Cu
  Mechanism for bone healing: Stimulates bone morphogenic proteins; promotes collagen synthesis relevant to bone callus matrix formation
  Evidence: In vitro data (Pickart, 2008); no animal or human RCT for bone healing
  FDA status: Not FDA-approved; available through compounding pharmacies for topical use
  SP availability: Not currently available through Superpower for this use
  Route: Topical or subcutaneous injection

BPC-157 is outside any FDA-permissible compounding category following its removal from the Category 2 list on April 22, 2026. Its inclusion is for educational context only.

Peptides Studied for Bone Healing: Individual Profiles

Each compound has a different mechanism, evidence base, and regulatory classification. None carries FDA approval for bone healing. Each requires a separate clinical evaluation.

BPC-157

BPC-157 is a synthetic 15-amino-acid pentadecapeptide. It is not FDA-approved for any indication. As of April 22, 2026, FDA removed BPC-157 from the Category 2 list of bulk drug substances under 503A/503B consideration; this places BPC-157 outside any FDA-permissible compounding category. The foundational bone healing citation is a 1999 paper by Sebecic and colleagues published in Bone, reporting osteogenic effects of BPC-157 on segmental bone defects in rabbits, with outcomes characterized by the authors as similar in scale to bone marrow and cortical bone implantation controls. This preclinical animal study remains the primary citation for BPC-157 in bone healing.

The proposed mechanism for BPC-157's bone healing activity runs through two pathways. First, pro-angiogenesis: callus formation requires vascular invasion of the fracture hematoma, and BPC-157's VEGF-pathway activity, documented by Brcic and colleagues in the Journal of Physiology and Pharmacology in 2009, describing BPC-157's proposed VEGF-mediated angiogenesis activity in musculoskeletal healing, makes it mechanistically relevant to this phase. Second, collagen matrix support: callus remodeling requires dense collagen scaffolding, and Seiwerth and colleagues, in Frontiers in Pharmacology in 2021, reviewed BPC-157's wound healing activity across collagen-rich tissues, documenting preclinical collagen-stimulating effects. A 2026 review by Matek and colleagues in Pharmaceuticals reviewed BPC-157's effects at the tendon, ligament, muscle, and bone junction in preclinical models — a body of work that has been cited in fracture recovery discussions though not tested in fracture-specific human trials. Yuan and colleagues in 2026 in the International Journal of Molecular Sciences also documented BPC-157's preclinical pain-modulating activity alongside structural repair effects in animal models. Jozwiak and colleagues, in Pharmaceuticals in 2025, provided a comprehensive BPC-157 literature and patent review, acknowledging the compound's broad and not-yet-fully-mapped preclinical pharmacology, including reported bone effects in animal models.

A 2025 systematic review by Vasireddi and colleagues in the HSS Journal reviewed BPC-157 across orthopaedic sports medicine, confirming preclinical-only evidence for bone and noting the absence of human RCT data. A 2025 narrative review by McGuire and colleagues in Current Reviews in Musculoskeletal Medicine provided additional honest framing of the emerging evidence. A 2026 review by Mendias and colleagues in Sports Medicine reinforced the evidence-gap framing for unapproved peptide therapies in musculoskeletal applications. [Animal study; no completed human RCT]

As of April 22, 2026, BPC-157 is not FDA-approved for any indication and is outside any FDA-permissible compounding category. Not available through Superpower or any licensed prescriber for this use. A 2026 review by Rahman and colleagues in JAAOS Global Research and Reviews reviewed therapeutic peptides in orthopaedics, situating BPC-157 within an evolving clinical development pipeline where regulatory approval remains a distant prospect. Physician-supervised protocols are the appropriate clinical context, as noted by Mayfield and colleagues in the American Journal of Sports Medicine in 2026 in their primer on injectable peptide therapies.

GH secretagogues (ipamorelin, CJC-1295, sermorelin)

GH secretagogues, growth hormone-releasing peptides (GHRPs) and GHRH analogs, stimulate the pituitary gland to secrete endogenous growth hormone, which drives hepatic IGF-1 production. Ipamorelin is a selective GHRP; CJC-1295 is a GHRH analog; sermorelin is a truncated GHRH analog. None are FDA-approved for bone healing or osteoporosis. All three have historically been compounded by 503A pharmacies; at its April 22, 2026 meeting, PCAC recommended against including CJC-1295 and ipamorelin on the 503A Bulks List, and sermorelin is under the same FDA and PCAC review. 503A availability for all three is actively contracting.

The bone-relevant mechanism is IGF-1-mediated osteoblast stimulation. A 2022 review by Tresguerres and colleagues in the International Journal of Molecular Sciences reviewed GH effects on multiple aging organs, including bone-specific data on GH/IGF-1-mediated osteoblast stimulation and bone mineral density in aging. The review by Giustina, published in Endocrinology and Metabolism in 2023, examined the relationship between GH levels and bone mineral density using the acromegaly model, demonstrating that GH excess is associated with higher BMD while GH deficiency is associated with lower BMD. Whether GH secretagogue use translates these observations into clinical benefit for bone maintenance has not been tested in adequate human trials. Jing and colleagues, in Acta Orthopaedica Belgica in 2024, examined osteoblast activity and fracture healing via miR-656-3p downregulation in a preclinical model, a pathway that GH/IGF-1 signaling may partially modulate. Raleigh and colleagues, in the Bone and Joint Journal in 2025, compared BMP-2 versus PDGF for nonunion treatment in a critical-sized defect model, illustrating the growth-factor-driven landscape within which GH secretagogues are positioned. Exercise is also relevant to bone density: a 2026 systematic review and network meta-analysis by Zhou and colleagues in the Journal of Sport and Health Science examined exercise effects on bone mineral density in postmenopausal women, providing complementary lifestyle context alongside peptide-based strategies. [Epidemiological / Mechanistic; no completed RCT for fracture healing]

Ipamorelin, CJC-1295, and sermorelin are not FDA-approved for bone healing or osteoporosis. They have historically been compounded by 503A pharmacies pursuant to individual patient prescriptions; however, at its April 22, 2026 meeting, PCAC recommended AGAINST including CJC-1295 and ipamorelin on the 503A Bulks List, and sermorelin as a GHRH analog is under the same FDA and PCAC review. Once FDA acts on the PCAC recommendations, 503A compounding of these peptides using bulk drug substances will no longer be available. Bone healing is not an FDA-approved indication, and safety and efficacy for fracture healing have not been established through adequate and well-controlled clinical trials. These compounds are not currently offered through Superpower for bone healing. Sermorelin has a prior FDA-approval history (Geref, withdrawn in 2008) and is now available only via compounding, subject to the same Bulks List review. IGF-1 monitoring is standard practice during any GH secretagogue protocol.

GHK-Cu

GHK-Cu is a naturally occurring tripeptide copper complex. In the bone context, its proposed relevance is through stimulation of bone morphogenic proteins (BMPs), the growth factors central to osteoblast differentiation and bone matrix mineralization. Pickart's foundational 2008 paper in the Journal of Biomaterials Science, Polymer Edition, documented GHK-Cu's tissue remodeling role including stimulation of bone morphogenic proteins, the primary citation supporting GHK-Cu's potential secondary bone-matrix effects. GHK-Cu has been reported to stimulate collagen synthesis in preclinical models, a mechanism that has been extrapolated to the collagen scaffolding phase of bone callus formation though not demonstrated in bone-specific models. DeFoor and colleagues, in Arthroscopy in 2025, situated injectable peptides including GHK-Cu within the regenerative medicine context. [In vitro; no completed animal or human RCT for bone healing]

GHK-Cu is widely sold as a cosmetic ingredient in topical products. It does not appear on FDA's Category 1 list of bulk drug substances for 503A compounding and lacks a USP monograph as a pharmaceutical API. Compounded injectable GHK-Cu preparations from US pharmacies do not have a clearly established 503A basis and may face FDA enforcement risk. Not currently available through Superpower for bone healing. Evidence is preclinical only.

Regulatory Status at a Glance

As of April 2026, the peptides discussed in this article carry different regulatory statuses for bone healing applications.

• BPC-157: Not FDA-approved for any indication; removed from FDA Category 2 list on April 22, 2026; outside any FDA-permissible compounding category; not eligible for 503A compounding and not legally available through US licensed prescribers. PCAC review remains pending separately.
• Ipamorelin / CJC-1295 / Sermorelin: Not FDA-approved for bone healing or osteoporosis. Historically compounded under Section 503A; at the April 22, 2026 PCAC meeting, PCAC recommended AGAINST including CJC-1295 and ipamorelin on the 503A Bulks List; sermorelin is under the same FDA and PCAC review. 503A availability is actively contracting. Sermorelin has a prior FDA-approval history (Geref, withdrawn in 2008).
• GHK-Cu: Not FDA-approved; sold as a cosmetic ingredient in topical products; does not appear on FDA's Category 1 list of bulk drug substances for 503A compounding and lacks a USP monograph. Compounded injectable GHK-Cu preparations do not have a clearly established 503A basis and may face FDA enforcement risk; not approved for bone healing.

BPC-157 is not legal to prescribe, compound, or sell for human use under current FDA regulatory posture. Its presence in this article is for educational context only.

Considerations When Comparing Peptides for Bone Healing

Selecting among these compounds is a clinical decision requiring physician expertise in bone health and fracture management, not a consumer choice. Direct comparison is not straightforward: BPC-157's direct bone data are from a single animal model; GH secretagogues' bone effects are extrapolated from population-level epidemiological data; GHK-Cu's relevant evidence is in vitro only. Inferring relative effectiveness across these different evidence bases is methodologically unsound.

Fracture type and healing trajectory: Uncomplicated long-bone fractures in younger adults with adequate nutrition and normal GH/IGF-1 have high natural healing rates. The clinical case for adjunct peptide therapy is stronger for delayed unions, nonunion risk, osteoporotic fractures in aging populations, or segmental defects where natural healing is impaired.

GH/IGF-1 axis status: IGF-1 reflects GH-axis activity and is a standard safety and monitoring baseline for any GH secretagogue protocol. A clinical decision to use a GH secretagogue for any indication — including any off-label use in fracture healing — is the prescribing provider's sole clinical responsibility, subject to applicable state medical-board standards; there is no FDA-approved indication for GH secretagogue use in fracture healing, and no major endocrinology society clinical practice guideline endorses GH secretagogue therapy based on a single low-normal IGF-1 result.

Nutritional and metabolic adequacy: Bone healing is nutrient-dependent. Vitamin D insufficiency, calcium inadequacy, and protein deficiency are common and addressable causes of impaired fracture healing. A provider will assess these before considering any additional compound.

Complementarity with standard fracture care: Standard fracture management (immobilization, weight-bearing protocols, nutritional optimization) has strong evidence. Any peptide adjunct would be considered alongside, not instead of, standard care. Raleigh and colleagues' 2025 comparison of BMP-2 and PDGF for nonunion illustrates where growth-factor approaches fit in advanced fracture management; peptides are further back in that development pipeline.

This is not an exhaustive list of clinical considerations. A licensed provider will evaluate your full history, imaging, and baseline biomarkers before recommending any adjunct.

Safety Considerations

GH secretagogues have compounding pharmacy safety data and established monitoring parameters. The primary safety concern with GH secretagogues is IGF-1 elevation above reference range, which carries proliferative concerns particularly in patients with a history of malignancy. BPC-157 and GHK-Cu have preclinical safety data only; no long-term human safety data exist. A 2026 review by Mendias and colleagues in Sports Medicine noted rigorous human safety data are scarce for unapproved peptides.

Contraindications that apply broadly to peptide therapy for bone healing include:

• Active or history of hormone-sensitive malignancy, including osteosarcoma: IGF-1-stimulating compounds carry theoretical proliferative concern; BPC-157's growth-promoting activity has not been characterized in post-malignancy settings
• Acromegaly or untreated GH excess: GH secretagogues are absolutely contraindicated
• Pregnancy: no reproductive safety data exist for any compound in this list
• Active infection at or near the fracture site: injectable peptides are not appropriate in the setting of local infection

For compound-specific safety profiles, consult a licensed healthcare provider and review the ISI block at the bottom of this page.

What to Test Before Starting Peptides for Bone Healing

Regardless of which compound is being discussed, baseline biomarker testing establishes the objective foundation for any fracture management adjunct. Without it, there is no way to assess whether metabolic bone health factors are contributing to impaired healing, or whether any intervention is producing measurable biological change.

• IGF-1: The primary downstream marker of GH axis activity and an anabolic signal for osteoblasts. Testing IGF-1 levels before any GH secretagogue protocol is standard clinical practice. It also establishes whether the GH/IGF-1 axis is a contributing factor in impaired bone healing.
• Vitamin D (25-hydroxy): Vitamin D is essential for calcium absorption and bone mineralization. Deficiency is a common and reversible cause of impaired fracture healing. Measuring 25-hydroxy vitamin D is a mandatory component of any bone health workup before additional interventions are layered on top.
• Alkaline phosphatase (ALP): Bone-specific ALP reflects osteoblast activity and bone turnover. Monitoring alkaline phosphatase at baseline and during any bone-healing protocol provides a functional indicator of osteoblast activity and matrix mineralization.
• Calcium: Serum calcium reflects the availability of the primary mineral substrate for bone mineralization. A calcium measurement at baseline is part of the standard pre-treatment metabolic bone assessment.
• Comprehensive metabolic panel: Liver enzymes and kidney function establish safety baselines for any injectable protocol. Renal function is particularly relevant because impaired kidney function affects both calcium metabolism and peptide clearance.
• Parathyroid hormone (PTH): PTH regulates calcium homeostasis and bone turnover. Elevated PTH (secondary hyperparathyroidism) is a common cause of impaired bone healing that must be identified and addressed before any additional intervention is considered.

Testing for joint and bone health biomarkers gives your provider the objective baseline needed to understand your musculoskeletal biology before recommending any adjunct compound.

How to Access These Peptides Safely

GHRH analogs and GHRPs — ipamorelin, CJC-1295, sermorelin — have historically been prescribed through 503A compounding pharmacies with physician oversight. At its April 22, 2026 meeting, PCAC recommended AGAINST including CJC-1295 and ipamorelin on the 503A Bulks List; sermorelin is under the same FDA and PCAC review umbrella. 503A availability is actively contracting. Any provider evaluation for these compounds should include IGF-1 baseline testing, health history review, and assessment of the fracture healing context. Teriparatide (Forteo) and abaloparatide (Tymlos), which are FDA-approved for osteoporosis with Phase 3 RCT evidence supporting their approved indication, provide the appropriate clinical reference point for evidence-based bone peptide therapy.

BPC-157 is not legally available through licensed prescribers in the US. As of April 22, 2026, BPC-157 is outside any FDA-permissible compounding category following its removal from the Category 2 list. Products sold online as BPC-157 operate outside FDA oversight. A 2018 review by Seiwerth and colleagues in Current Pharmaceutical Design reviewed BPC-157's angiogenic growth factor interactions across tissue healing contexts, but the preclinical depth of the literature does not substitute for clinical trial data or regulatory approval. A 2019 review by Gwyer and colleagues reviewed BPC-157's musculoskeletal application breadth while noting the same clinical translation gap. The Staresinic 2022 Biomedicines review documented BPC-157's effects across muscle types including its vascular recruitment activity relevant to bone callus vascularization: mechanistically described, clinically unvalidated.

Understanding Your Baseline

Bone healing is not a passive process. It is an active metabolic event that requires adequate GH/IGF-1 signaling, sufficient vitamin D and calcium, normal parathyroid function, and a systemic environment that supports osteoblast activity. A fracture is one of the clearest instances where objective biomarker data directly influences clinical decision-making. Knowing your IGF-1 level, vitamin D status, and ALP baseline tells your provider whether the anabolic machinery needed for callus formation is adequately supplied, before any adjunct compound is considered.

That principle, test first, then decide, is central to Superpower's approach to preventive health. Whether the conversation leads to vitamin D supplementation, a GH secretagogue protocol, or a standard orthopedic course of care, the starting point is the same: knowing where your biomarkers stand.

IMPORTANT SAFETY INFORMATION

BPC-157 is not approved by the FDA for any medical use. As of April 22, 2026, FDA removed BPC-157 from the Category 2 list of bulk drug substances under 503A/503B consideration. Removal is not equivalent to Category 1 approval; BPC-157 is outside any FDA-permissible compounding category, is not eligible for 503A compounding, and is not legally available through US licensed prescribers. PCAC review remains pending separately. Research is limited primarily to animal studies, including bone defect models. Safety, efficacy, appropriate dosing, and long-term effects in humans for bone healing have not been established. BPC-157 is not prescribed, compounded, or dispensed through Superpower. Products sold online as BPC-157 operate outside FDA oversight; FDA has warned of contaminated and counterfeit "research peptide" products.

Ipamorelin, CJC-1295, and sermorelin are not FDA-approved for bone healing or osteoporosis indications. Bone healing is not an FDA-approved indication for any GHRH analog or GHRP, and these compounds are not offered through Superpower for bone healing. Any off-indication compounded use is the prescribing provider's sole clinical responsibility. Where these compounds have historically been compounded under Section 503A, that pathway is actively contracting following the April 22, 2026 PCAC recommendation against CJC-1295 and ipamorelin Bulks List inclusion. IGF-1 monitoring is standard during any GH secretagogue protocol. Contraindicated in acromegaly, untreated GH excess, or history of hormone-sensitive malignancy. Safety and efficacy for fracture healing have not been established through adequate and well-controlled clinical trials.

GHK-Cu is not FDA-approved for any indication. It is widely sold as a cosmetic ingredient in topical products; it does not appear on FDA's Category 1 list of bulk drug substances for 503A compounding and lacks a USP monograph. Compounded injectable GHK-Cu preparations do not have a clearly established 503A basis and may face FDA enforcement risk. Evidence for bone healing is limited to in vitro data. Not currently available through Superpower for this use.

This article is provided for educational and informational purposes only and does not constitute medical advice. Fracture management requires physician oversight. Consult a licensed healthcare provider before starting any peptide therapy. Full FDA-approved prescribing information at dailymed.nlm.nih.gov.

Disclaimer: This article discusses peptide compounds for bone healing with different regulatory statuses. As of April 22, 2026, BPC-157 has been removed from the FDA Category 2 list and is outside any FDA-permissible compounding category; GH secretagogues are compounded under 503A for provider-determined indications; GHK-Cu is not approved for this use. None are FDA-approved for bone healing. This educational content is editorially independent.